Form 4 for PCVX Vaxcyte, Inc.
Accepted 2026-06-03 16:59:15 ET · period of report 2026-06-01 · accession 0001813798-26-000011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-06-03 16:59 | 2026-06-01 | PCVX | Wassil Jim | COO | S - Sale | $49.52 | -2,250 | 158.5K | -1% | -$111.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-01 | S | D | 1,949 | $49.40 | 158,795 | D | — | — | (F1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $49.03 to $49.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2026-06-01 | S | D | 301 | $50.26 | 158,494 | D | — | — | (F1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $50.205 to $51.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |